Effects of higenamine and its 1-naphthyl analogs, YS-49 and YS-51, on platelet TXA2 synthesis and aggregation

Thrombosis Research

Volumn 120, Issue 1, 2007, Pages 81-86

  Pyo, Mi Kyung ^a   Kim, Jeong Mi ^a   Jin, Jing Ling ^a   Chang, Ki Churl ^b   Lee, Duck Hyung ^c   Yun Choi, Hye Sook ^a  

^a Seoul National University   (South Korea)

^b Gyeongsang National University School of Medicine   (South Korea)

^c Sogang University   (South Korea)

Author keywords

Higenamine; TP receptor; TXA2 production; YS 49; YS 51

Indexed keywords

1 NAPHTHOL DERIVATIVE; 15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; ALPHA 2 ADRENERGIC RECEPTOR; ARACHIDONIC ACID; HIGENAMINE; METHYL GROUP; TETRAHYDROISOQUINOLINE; THROMBOXANE A2; THROMBOXANE A2 RECEPTOR; THROMBOXANE A2 RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG; YS 49; YS 51;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; HUMAN; HYDROPHOBICITY; IC 50; INHIBITION KINETICS; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; RAT; THROMBOCYTE AGGREGATION; THROMBOCYTOPOIESIS;

ADULT; ALKALOIDS; ANIMALS; BLOOD PLATELETS; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; PLATELET AGGREGATION; RATS; RATS, SPRAGUE-DAWLEY; TETRAHYDROISOQUINOLINES; THROMBOXANE A2; TREATMENT OUTCOME;

EID: 34247157378     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2006.07.006     Document Type: Article

References (31)

1. Kosuge T., and Yokota M. Studies on cardiac principle of Aconite root. Chem Pharm Bull 24 (1976) 176-178
2. Kosuge T., Yokota M., and Nagasawa M. Studies on cardiac principle in Aconite roots: I. Isolation and structure determination of higenamine. Yakugaku Zasshi 98 (1978) 1370-1375
3. Kosuge T., Yokota M., Nukya H., Gotoh Y., and Nagasawa M. Studies on antitussive principles of Asiasari radix. Chem Pharm Bull 26 (1978) 2284-2285
4. Leboeuf M., Cavé A., Touché A., Provost J., and Forgacs P. Isolement de I'higémanine a partir de I'Amnnona squamosa; interet des résins adsorbantes macromolécularies en chimie végétale extractive. J Nat Prod 44 (1981) 53-60
5. Xu Q., and Lin M. Benzylisoquinoline alkaloids from Genetum parvifolium. J Nat Prod 62 (1999) 1025-1027
6. Park C.W., Chang K.C., and Lim J.K. Effects of higenamine on isolated heart adrenoceptor of rabbit. Arch Int Pharmacodyn 167 (1984) 279-288
7. Chang K.C., Chong W.S., and Lee I.J. Different pharmacological characteristics of structurally similar benzylisoquinoline analogs, papaverine, higenamine, and GS 389, on isolated rat aorta and heart. Can J Physiol Pharmacol 72 (1994) 327-334
8. Chong W.S., Lee Y.S., Kang Y.J., Lee D.H., Ryu J.C., Yun-Choi H.S., et al. Comparision of inodilator effect of higenamine, YS-49, YS-51, tetrahydroisoquinoline analogs, and Dobutamine in the rat. Korean J Physiol Pharmacol 2 (1998) 323-330
9. Yun-Choi H.S., Pyo M.K., Park K.M., Chang K.C., and Lee D.H. Anti-thrombotic effects of higenamine. Planta Med 67 (2001) 619-622
10. Kang Y.J., Lee G.W., Ku E.B., Lee H.Y., and Chang K.C. Inhibition of higenamine of LPS-induced iNOS mRNA expression and NO production in rat aorta. Korean J Physiol Pharmacol 1 (1997) 297-302
11. Kang Y.J., Lee Y.S., Lee G.W., Lee D.H., Ryu J.C., Yun-Choi H.S., et al. Inhibition of activation of nuclear factor κB is responsible for inhibition of inducible nitric oxide synthase expression by higenamine, an active component of Aconite root. J Pharmacol Exp Ther 291 (1999) 314-320
12. Lee H.Y., Lee J.S., Kim E.J., Han J.W., Lee H.W., Kang Y.J., et al. Inhibition of lipopolysaccharide-induced inducible nitric oxide synthase (iNOS) mRNA expression and nitric oxide production by higenamine in murine peritoneal macrophages. Arch Pharm Res 22 (1999) 55-59
13. Lee Y.S., Kim C.H., Yun-Choi H.S., and Chang K.C. Cardiovascular effect of a naphthylmethyl substituted tetrahydroisoquinoline, YS-49 in rat and rabbit. Life Sci 55 (1994) PL415-PL420
14. Kang Y.J., Koo E.B., Lee Y.S., Yun-Choi H.S., and Chang K.C. Prevention of the expression of inducible nitric oxide synthase by a novel positive inotropic agent, YS-49, in rat vascular smooth muscle and RAW 264.7 macrophages. Br J Pharmacol 128 (1999) 357-364
15. Jung T.H., Lee Y.S., Kang Y.J., Lee B.K., Ko Y.S., Seo H.G., et al. Inhibition of tumor necrosis factor-α mRNA expression by a limited series of tetrahydroisoquinolines in mouse peritoneal macrophages. Korean J Physiol Pharmacol 4 (2000) 325-331
16. Kang Y.J., Seo S.J., Yun-Choi H.S., Lee D.H., Kim Y.M., and Chang K.C. A synthetic isoquinoline alkaloid, 1-(β-naphthylmethyl)-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline (YS-51), reduces inducible nitric oxide synthase expression and improves survival in a rodent model of endotoxic shock. J Pharmacol Exp Ther 301 (2002) 561-567
17. Yun-Choi H.S., Pyo M.K., Park K.M., Chang K.C., and Lee D.H. Antithrombotic effects of YS-49 and YS-51-1-naphthylmethyl analogs of higenamine. Thromb Res 104 (2001) 249-255
18. Yun-Choi H.S., Pyo M.K., Chang K.C., and Lee D.H. The effects of higenamine on LPS-induced experimental disseminated intravascular coagulation (DIC) in rats. Planta Med 68 (2002) 326-329
19. Pyo M.K., Yun-Choi H.S., Chang K.C., and Lee D.H. Effects of two tetrahydroisoquinolines (YS-49 and YS-51) on experimental disseminated intravascular coagulation induced by lipopolysaccharide in rats. Arzneim Forsch Drug Res 54 (2004) 705-710
20. Chang K.C., Yun-Choi H.S., Lim J.K., and Park C.W. Synthesis of higenamine; a cardiotonic principle of Aconite root. Arch Pharm Res 7 (1984) 133-136
21. Chang K.C., Kang Y.J., Lee Y.S., Chong W.S., Yun-Choi H.S., Lee D.H., et al. Pharmacological characterization of synthetic tetrahydroisoquinoline alkaloids, YS 51 and YS 55, on the cardiovascular system. Korean J Physiol Pharmacol 2 (1998) 461-469
22. McNicol A. Platelet preparation and estimation of functional responses. In: Watson S.P., and Authi K.S. (Eds). Platelets-a practical approach (1996), Oirl Press at Oxford University Press 1-12
23. 2 by the action of collagen on rat platelets. Thromb Res 46 (1987) 425-436
24. Yun-Choi H.S., Park K.M., and Pyo M.K. Epinephrine induced platelet aggregation in at platelet rich plasma. Thromb Res 100 (2000) 511-518
25. 2 receptors: where have you gone?. Prostaglandins Lipid Mediat 60 (2000) 175-189
26. Rand M.L., Leung R., and Packham M.A. Platelet function assays. Transfus Apher Sci 28 (2003) 307-317
27. Ahn C., Romstedt K.J., Wallace L.J., Miller D.D., and Feller D.R. Characterization of the inhibition of U46619 mediated human platelet activation by the trimetoquinol isomers. Biochem Pharmacol 37 (1988) 3023-3033
28. 2 antagonists with diminished β-adrenergic agonist activity. J Med Chem 40 (1997) 85-91
29. 2 and prostacyclin. Pharmacol Rev 30 (1978) 293-331
30. 2 receptors. Cell Signal 16 (2004) 521-533
31. Dogné J.M., Hanson J., and Pratico D. Thromboxane, prostacyclin and isoprostanes: therapeutic targets in atherogenesis. Trends Pharmacol Sci 26 (2005) 639-644